QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine

References

• van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–67.
   PubMed Web of Science ®Google Scholar
• Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44(2):173–5.
   PubMed Web of Science ®Google Scholar
• Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J Clin Rheumatol 2013;19(5):286–8.
   PubMed Web of Science ®Google Scholar
• Jankelson L, Karam G, Becker ML, Chinitz LA, Tsai MC. QT prolongation, torsade de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart Rhythm. 2020;17(9):1472–8.
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020;383(21):2041–52.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91.
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika 1983;70(1):41–55.
   Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.
   PubMed Web of Science ®Google Scholar
• Dekker JM, Crow RS, Hannan PJ, Schouten EG, Folsom AR, ARIC Study. Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study. J Am Coll Cardiol. 2004;43(4):565–71.
   PubMed Web of Science ®Google Scholar
• Oka H, Mochio S, Sato K, Sato H, Katayama K. Prolongation of QTc interval and autonomic nervous dysfunction in diabetic patients. Diabetes Res Clin Pract. 1996;31(1-3):63–70.
   PubMed Web of Science ®Google Scholar
• Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil. 2005;12(4):363–8.
   PubMedGoogle Scholar
• Williams ES, Thomas KL, Broderick S, Shaw LK, Velazquez EJ, Al-Khatib SM, et al. Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: results from the Duke Databank for Cardiovascular Disease (DDCD). Am Heart J.2012;164(3):434–41.
   PubMed Web of Science ®Google Scholar
• Johnson JN, Grifoni C, Bos JM, Saber-Ayad M, Ommen SR, Nistri S, et al. Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Europ Heart J.2011;32(9):1114–20.
   PubMed Web of Science ®Google Scholar
• White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377–99.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
   PubMed Web of Science ®Google Scholar
• Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153(6):891–9.
   PubMed Web of Science ®Google Scholar
• Kim KA, Park JY, Lee JS, Lim S. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003;26(8):631–7.
   PubMed Web of Science ®Google Scholar
• Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N‐desethylchloroquine formation. Drug Metab Dispos. 2003;31(6):748–54.
   PubMed Web of Science ®Google Scholar
• Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol. 2007;40(3):228–34 e8.
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, Berger RD, et al. Traditional Framingham risk scores fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum.2001;44(10):2331–7.
   PubMed Web of Science ®Google Scholar
• Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med.1992;93(5):513–9.
   PubMed Web of Science ®Google Scholar
• Toloza SMA, Uribe AG, McGwin G, Jr, Alarcon GS, Fessler BJ, Bastian HM, LUMINA Study Group, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 2004;50(12):3947–57.
   PubMed Web of Science ®Google Scholar
• Hooks M, Bart B, Vardeny O, Westanmo A, Adabag S. Effects of hydroxychloroquine treatment on QT interval. Heart Rhythm.2020;17(11):1930–7.
   PubMed Web of Science ®Google Scholar
• Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348(19):1866–74.
   PubMed Web of Science ®Google Scholar
• Davila L, Ranganathan P. Pharmacogenetics: implications for therapy in rheumatic diseases. Nat Rev Rheumatol. 2011;7(9):537–50.
   PubMed Web of Science ®Google Scholar
• Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002;30(6):631–5.
   PubMed Web of Science ®Google Scholar
• Amundsen R, Asberg A, Ohm IK, Christensen H. Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. Drug Metab Dispos. 2012;40(4):655–61.
   PubMed Web of Science ®Google Scholar
• Niwa T, Yamamoto S, Saito M, Shiraga T, Takagi A. Effect of cyclosporine and tacrolimus on cytochrome P450 activities in human liver microsomes. Yakugaku Zasshi. 2007;127(1):209–16.
   PubMed Web of Science ®Google Scholar
• Brüggemann RJM, Alffenaar JC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441–58.
   PubMed Web of Science ®Google Scholar
• Park E, Giles J, Perez-Recio T, Pina P, Depender C, Bathon J, et al. Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients [abstract]. Arthritis Rheumatol 2020;72(suppl 10).
   Google Scholar